Biomarker-Driven Bioanalysis

Biomarker-driven bioanalysis provides the quantitative data essential for biopharma decision-making across the drug development pipeline. As therapeutic modalities expand from mAbs and ADCs to cell & gene therapies and oligonucleotides, demand grows for greater sensitivity, specificity, and robustness in complex matrices.

Biomarkers are objective indicators of biological processes, disease states, and pharmacological responses—guiding target validation, patient stratification, dose selection, and safety monitoring. With the FDA and EMA increasingly embedding biomarker frameworks into trial design, accurate biomarker quantification has become foundational for advancing novel therapeutics.

ACROBiosystems offers integrated biomarker-driven bioanalysis solutions spanning biomarker research, assay development, and translational support. Our recombinant proteins, assay kits, critical reagents, and custom services enable accurate and reliable quantification of biomarkers across diverse therapeutic modalities and throughout the drug development continuum.